The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Today, a brief rundown of news from J&J and the FDA, as well as updates from Sage Therapeutics, Roche and Enanta Pharmaceuticals that you may have missed. Recent biotech company acquisitions have put ...

Arch Venture Partners, a prominent creator of biotechnology startups, has raised more than $3 billion for its 13th fund, the firm announced Thursday. The fundraise comes only two years after Arch ...

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.

The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached ...

BioBridges has been a trusted partner in the life sciences industry for more than 20 years. With the launch of its new ...

The financing will support a technology designed to make delivery of lentiviral gene therapies, which are typically administered through a complex process, more convenient.

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.